Long EDIT @ trendline support
Updated
A tight stop could be set here but I went with a bit looser one that would confirm a break down from trendline. Could be held long term or short. Good risk:reward.
The topic of genesiology/eugenics may be ignored and considered morally reprehensible in modern society, but appears to be inevitable. I will ignore moral argument for this discussion.
The film Gattaca presents a vision of a future society driven by eugenics where potential children are conceived through genetic selection to ensure they possess the best hereditary traits of their parents. NASA has named Gattaca as the most accurate science fiction film of all time. Selective genesiology is inevitable.
This article reviews modern research aimed at making Gattaca the future. nerdist.com/20-year-anniversary-gattaca-genetics/ Some researches are quoted as saying genetic selection will be reality as soon as 5 years from now.
Gender and eye color can already be selected for with a procedure known as pre-implantation genetic diagnosis (PGD).
Key traits could include height and skin color. Susceptibility to cancer, heart disease, obesity, and genetic disease could also be on the table. Industries associated with these traits are already trillion dollar industries. Studies show height plays a major role in male social & financial success. Koreans and other asian culture pump millions into solutions to lighten their skin.
Gene replacement and repair with enzyme complex CRISPR/Cas9 has already been successfully performed in human embryos but 100% success has not been achieved and embryos have not been allowed to gestate. This technology will likely be used to revolutionize the agriculture industry before human applications are practical. Stocks in this category are highly dependent on the success or failure of the CRISPR-Cas9 procedure, and as the limitations of the procedure become more clear, stock prices will suffer.
Stocks
NASDAQ: NTLA Intellia Therapeutics Inc is a research company deticated to in vivo gene modication. Risky bet, highly depedent on CRISPR-Cas9 procedure Market Cap: 1.2B P/E: -- No entry currently watch for move down to daily volume node
NYSE:COO CooperSurgical is a business unit of The Cooper Companies, Inc., a global medical device company involved with IVF technologies Safe bet, dividends, earnings Market Cap: 11.2B P/E: 30 Entry available now with option for tight stop
NASDAQ: EDIT Editas Medicine is a biotechnology firm with a mission of using gene editing to treat disease. Risky bet, highly depedent on CRISPR-Cas9 procedure Market cap: 1.8B P/E: --
CRSP Biotechnology start up company based on CRISPR-Cas9 genome editing Risky bet, highly depedent on CRISPR-Cas9 procedure Market cap: 3.2B P/E: --
ARKG ETF of genome companies (includes most of the above companies)
Articles
NASA has named Gattaca as the most accurate science fiction film of all time. theatlantic.com/entertainment/archive/2011/01/nasa-calls-2012-silliest-sci-fi-film-of-all-time-says-jurassic-park-is-scientifically-plausible/69049/
This article reviews modern research aimed at making Gattaca the future. nerdist.com/20-year-anniversary-gattaca-genetics/
Over 5,000,000 babies have been born using IVF assisted technologies (which can allow for selection of eye color and gender) livescience.com/21355-5-million-babies-born-ivf-technologies.html
Gene replacement and repair with enzyme complex CRISPR/Cas9 Performed (this is the complex that allows for discovery of genes related to various diseases, even baldness, height, etc) nature.com/news/chinese-scientists-genetically-modify-human-embryos-1.17378
CRISPR patent legal battle (update on ongoing legal battle between Editas Medicine (NASDAQ:EDIT) and CRISPR patent holder) scientificamerican.com/article/all-you-need-to-know-for-round-2-of-the-crispr-patent-fight/
Podcast about Gattaca,
The topic of genesiology/eugenics may be ignored and considered morally reprehensible in modern society, but appears to be inevitable. I will ignore moral argument for this discussion.
The film Gattaca presents a vision of a future society driven by eugenics where potential children are conceived through genetic selection to ensure they possess the best hereditary traits of their parents. NASA has named Gattaca as the most accurate science fiction film of all time. Selective genesiology is inevitable.
This article reviews modern research aimed at making Gattaca the future. nerdist.com/20-year-anniversary-gattaca-genetics/ Some researches are quoted as saying genetic selection will be reality as soon as 5 years from now.
Gender and eye color can already be selected for with a procedure known as pre-implantation genetic diagnosis (PGD).
Key traits could include height and skin color. Susceptibility to cancer, heart disease, obesity, and genetic disease could also be on the table. Industries associated with these traits are already trillion dollar industries. Studies show height plays a major role in male social & financial success. Koreans and other asian culture pump millions into solutions to lighten their skin.
Gene replacement and repair with enzyme complex CRISPR/Cas9 has already been successfully performed in human embryos but 100% success has not been achieved and embryos have not been allowed to gestate. This technology will likely be used to revolutionize the agriculture industry before human applications are practical. Stocks in this category are highly dependent on the success or failure of the CRISPR-Cas9 procedure, and as the limitations of the procedure become more clear, stock prices will suffer.
Stocks
NASDAQ: NTLA Intellia Therapeutics Inc is a research company deticated to in vivo gene modication. Risky bet, highly depedent on CRISPR-Cas9 procedure Market Cap: 1.2B P/E: -- No entry currently watch for move down to daily volume node
NYSE:COO CooperSurgical is a business unit of The Cooper Companies, Inc., a global medical device company involved with IVF technologies Safe bet, dividends, earnings Market Cap: 11.2B P/E: 30 Entry available now with option for tight stop
NASDAQ: EDIT Editas Medicine is a biotechnology firm with a mission of using gene editing to treat disease. Risky bet, highly depedent on CRISPR-Cas9 procedure Market cap: 1.8B P/E: --
CRSP Biotechnology start up company based on CRISPR-Cas9 genome editing Risky bet, highly depedent on CRISPR-Cas9 procedure Market cap: 3.2B P/E: --
ARKG ETF of genome companies (includes most of the above companies)
Articles
NASA has named Gattaca as the most accurate science fiction film of all time. theatlantic.com/entertainment/archive/2011/01/nasa-calls-2012-silliest-sci-fi-film-of-all-time-says-jurassic-park-is-scientifically-plausible/69049/
This article reviews modern research aimed at making Gattaca the future. nerdist.com/20-year-anniversary-gattaca-genetics/
Over 5,000,000 babies have been born using IVF assisted technologies (which can allow for selection of eye color and gender) livescience.com/21355-5-million-babies-born-ivf-technologies.html
Gene replacement and repair with enzyme complex CRISPR/Cas9 Performed (this is the complex that allows for discovery of genes related to various diseases, even baldness, height, etc) nature.com/news/chinese-scientists-genetically-modify-human-embryos-1.17378
CRISPR patent legal battle (update on ongoing legal battle between Editas Medicine (NASDAQ:EDIT) and CRISPR patent holder) scientificamerican.com/article/all-you-need-to-know-for-round-2-of-the-crispr-patent-fight/
Podcast about Gattaca,
Note
A thought re: this trade. EDIT could be a good hold for long term portfolio. The take profit point I chose was not based on anything in particular.Note
No clear case for closing this long early (or at all). No limit sell set.Note
DWDP is another good 'gattaca' stock that focuses on agriculture.Note
EDIT closed below daily trendline today and tomorrow should consider looking for an exit for long.Trade closed manually
Close @ 36.32 Sold based on daily candle closed below trendline, sold at retrace to trendline.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.